Duloxetine for the Treatment of Dysthymia
Trial ID or NCT#
Status
Purpose
The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.
Official Title
Duloxetine for the Treatment of Dysthymia
Eligibility Criteria
- : - Sign an informed consent form - 18 years of age or older - Females not pregnant or breastfeeding or planning pregnancy and using an acceptable form of contraception - Meet DSM-IV criteria for dysthymia - A screening IDS-C score of 17 or greater - No history of serious or unstable medical disorder - Not taking any significant concurrent medications - Not currently receiving psychotherapy
- - Suffering from DSM-IV defined - delirium, dementia, amnestic, or other cognitive disorders - mental disorders due to a general medical condition - factitious or somatoform disorders - mental retardation or developmental disabilities - substance or alcohol abuse within the last 3 months - depressive disorders with current suicidal risk - psychotic disorders including delusional disorder, somatic type - dissociative disorder - personality disorders sufficiently severe to interfere with study participation - History of DSM-IV defined bipolar I or II disorder - History of non-response of dysthymia to adequate antidepressant medication - History of major depression refractory to two adequate trials of antidepressants
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Nona Gamel
6507255180
View on ClinicalTrials.gov